Applying a proton beam in radiotherapy enables precise irradiation of the tumor volume, but only for continuous assessment of changes in patient anatomy. Proton beam range uncertainties in the treatment process may originate not only from physical beam properties but also from patient-specific factors such as tumor shrinkage, edema formation and sinus filling, which are not incorporated in tumor volume safety margins. In this paper, we evaluated variations in dose distribution in proton therapy resulting from the differences observed in the control tomographic images and the dosimetric influence of applied adaptive treatment. The data from weekly computed tomography (CT) control scans of 21 patients, which serve as the basis for adaptive radiotherapy, were used for this study. Dosimetric analysis of adaptive proton therapy (APT) was performed on patients with head and neck (H&N) area tumors who were divided into two groups: patients with tumors in the sinus/nasal area and patients with tumors in the brain area. For this analysis, the reference treatment plans were forward-calculated using weekly control CT scans. A comparative evaluation of organ at risk (OAR) dose-volume histogram (DVH) parameters, as well as conformity and homogeneity indices, was conducted between the initial and recalculated dose distributions to assess the necessity of the adaptation process in terms of dosimetric parameters. Changes in PTV volume after replanning were observed in seventeen patient cases, showing a discrepancy of over 1 in ten cases. In these cases, tumor progression occurred in 30% of patients, while regression was observed in 70%. The statistical analysis indicates that the use of the adaptive planning procedure results in a statistically significant improvement in dose distribution, particularly in the PTV area. The findings led to the conclusion that the adaptive procedure provides significant advantages in terms of dose distribution within the treated volume. However, when considering the entire patient group, APT did not result in a statistically significant dose reduction in OARs ( = 0.05).
Background: This work presents the procedures and application of the deep inspiration breath-hold (DIBH) technique for mediastinal lymphoma patients at a proton therapy (PT) center. It also discusses the implementation and validation of the surface-guided radiotherapy (SGRT) protocol in terms of positioning accuracy. Methods: This study included six lymphoma patients. Dedicated computed tomography (CT) protocols and a treatment workflow based on international guidelines were developed. Clinical data from the treatment planning system (TPS) were used to assess the difference between DIBH and free-breathing irradiation. Additionally, data from an optical patient positioning system and kilovoltage (kV) imaging system were used to estimate positioning shifts. The new CT protocol reduced the volume CT dose index by over six times compared with the standard protocol. Results: The DIBH method decreased the mean dose to the heart and lungs by up to 7.02 Gy(RBE) and 0.83 Gy(RBE), respectively. The median magnitude of patient setup errors and repeatability in DIBH positioning was 0.4 cm and 0.18 cm (mean for males and females) for the SGRT protocol. The kV imaging showed a setup error of over 0.3 cm for both groups. Conclusions: Despite the small size of the patient cohort, the relatively large number of individual positioning sessions enabled the detection of statistically significant differences (p < 0.05) in certain areas between male and female patients; however, no significant difference in the displacement vector magnitude was observed. DIBH treatment with SGRT offers high reproducibility for patient positioning.
1 January 2001 in Reports of Practical Oncology and Radiotherapy
StreszczenieW grupie 110 chorych operowanych z powodu raka trzonu macicy oceniono tolerancję uzupełniającej pulsacyjnej brachyterapii dopochwowej. Wczesny odczyn popromienny o lekkim przebiegu w pochwie i w odbytnicy wystapił łąpznie u 9 chorych (8.2%), późny u 6 chorych (5.5%). U jednej chorej wystapił odczyn popromienny w odbytnicy w stopniu czwartym. W okresie obserwacji nie stwierdzono wznowy w pochwie.Pulsacyjna brachyterapia dopochwpwa jest bezpieczną i skuteczną metodą uzupełniającego leczenia chorych operowanych z powodu raka trzonu macicy.SummaryIn a group of 110 patients operated on for endometrial carcinoma the tolerance of a supplementary pulsatile intravaginal brachytherapy was assessed. Early light post-radiation reaction in the vagina and in the anus was found in a total of 9 (8.2%) patients, whereas late reaction occurred in 6 (5.5%) patients. One patient showed the fourth degree post-radiation reaction in the anus. During the follow-up no remission was observed in the vagina.Pulsatile brachytherapy is a safe and effective supplementary method of treatment in patients operated on for endometrial carcinoma
1 January 2001 in Reports of Practical Oncology and Radiotherapy
SummaryPurposeVerification of reconstruction of application geometry and of calculations of dose distribution in the PLATO v. 13.7 system for brachytherapy treatment planning.Materials and methodsThe correctness of geometry reconstruction was verified using a Perspex phantom with lead markers. Dose calculations were verified by comparing values calculated by the system against values calculated „manually” and against published benchmark values.ResultsThe average difference between marker co-ordinates in the phantom, as measured mechanically, and as reconstructed by the PLATO system, did not exceed 0.4 mm. The maximum relative difference between values of dose at given points, calculated by the PLATO system and values of dose calculated „manually” at those points, did not exceed 0.3%. The PLATO system was found to correctly reproduce the published benchmark data.ConclusionsThe geometry reconstruction software module unit and the dose distribution algorithm of the PLATO v. 13.7 planning system used at the Centre of Oncology in Kraków, were found to operate correctly
12 December 2017 in Nowotwory. Journal of Oncology
Introduction. Because the specific proton beam dose distribution (i.e. the so-called ’Bragg curve’), proton radiotherapy ensures that the high-dose region is precisely confined to the target volume while minimizing the dose delivered to healthy tissues/critical organs surrounding the tumour or to those lying in the path of the proton beam. This method has been used for patients in Kraków since November 2016. Aim. To report the early tolerance outcomes to proton radiotherapy in patients completing their treatment just before the end of August 2017. Materials and methods. Study subjects were 47 patients who had completed their treatment before the end of August 2017 with a mean age of 41.6 years (range: 16–76, median: 40). The most frequent diagnoses were skull base tumours (22 pts. — 46.8%) and brain G1 or G2 gliomas (17 pts. — 36.2%), whereas the most frequent histological types were chordomas (17 pts. — 36.2%). Proton radiotherapy was administered by pencil beam scanning and consisted of using the intensity modulated proton therapy (IMPT) technique. The total dose given per cancer type averaged as follows: (i) 70 and 74 Gy(RBE), for respectively chodrosarcomas and chordomas, (ii) 54 Gy(RBE) for brain gliomas and (iii) 70 Gy(RBE) for paranasal sinuses tumours. Early tolerance was prospectively evaluated and measured according to the CTCAE scale, version 4.03. Results. In all, 91 side effects (SE) were recorded in 44 patients. The intensity of SEs were as following: 62 SEs (68.1%) were of grade 1 intensity, 21 SEs (23.1%) were of grade 2 and 8 SEs (8.8%) were of grade 3. The most frequently developed SEs were skin reactions (29 pts. — 61.7%) or oral/pharyngeal mucositis (20 pts. — 42.6%). Because the patient follow-up period was short, presented results only describes the early tolerance to this therapy. Our findings of mild intensities for the most early side effects, at (grades 1 or 2) are consistent with other published studies. Introduction. Because the specific proton beam dose distribution (i.e. the so-called ’Bragg curve’), proton radiotherapy ensures that the high-dose region is precisely confined to the target volume while minimizing the dose delivered to healthy tissues/critical organs surrounding the tumour or to those lying in the path of the proton beam. This method has been used for patients in Kraków since November 2016. Aim. To report the early tolerance outcomes to proton radiotherapy in patients completing their treatment just before the end of August 2017. Materials and methods. Study subjects were 47 patients who had completed their treatment before the end of August 2017 with a mean age of 41.6 years (range: 16–76, median: 40). The most frequent diagnoses were skull base tumours (22 pts. — 46.8%) and brain G1 or G2 gliomas (17 pts. — 36.2%), whereas the most frequent histological types were chordomas (17 pts. — 36.2%). Proton radiotherapy was administered by pencil beam scanning and consisted of using the intensity modulated proton therapy (IMPT) technique. The total dose given per cancer type averaged as follows: (i) 70 and 74 Gy(RBE), for respectively chodrosarcomas and chordomas, (ii) 54 Gy(RBE) for brain gliomas and (iii) 70 Gy(RBE) for paranasal sinuses tumours. Early tolerance was prospectively evaluated and measured according to the CTCAE scale, version 4.03. Results. In all, 91 side effects (SE) were recorded in 44 patients. The intensity of SEs were as following: 62 SEs (68.1%) were of grade 1 intensity, 21 SEs (23.1%) were of grade 2 and 8 SEs (8.8%) were of grade 3. The most frequently developed SEs were skin reactions (29 pts. — 61.7%) or oral/pharyngeal mucositis (20 pts. — 42.6%). Because the patient follow-up period was short, presented results only describes the early tolerance to this therapy. Our findings of mild intensities for the most early side effects, at (grades 1 or 2) are consistent with other published studies.